Literature DB >> 4041341

Ventilatory effects of long-term treatment with pindolol and metoprolol in hypertensive patients with chronic obstructive lung disease.

J W Lammers, H T Folgering, C L van Herwaarden.   

Abstract

Effects of long-term treatment with pindolol (10 mg twice daily) and metoprolol (100 mg twice daily) on lung function and blood pressure were investigated in eight patients with chronic obstructive lung disease and hypertension. After a placebo period, both beta-adrenoceptor blockers were administered double-blind and cross-over for 4 weeks. By assessing parameters of expiratory flow an attempt was made to distinguish between large and small airways function. Diastolic blood pressure decreased significantly during both pindolol and metoprolol (P less than 0.01). Except for a decrease in forced expiratory volume in 1 s (FEV1) during metoprolol treatment, there was no other change in expiratory flow parameters after placebo or both beta-adrenoceptor blockers. Inhalation of terbutaline induced a small improvement in large airways function after placebo and metoprolol, but not after pindolol; there was no effect of terbutaline on parameters of small airways function. If a beta-adrenoceptor blocker is necessary in patients with chronic obstructive lung disease, a beta 1-adrenoceptor selective blocker is preferred in combination with bronchodilator agents.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4041341      PMCID: PMC1400701          DOI: 10.1111/j.1365-2125.1985.tb05062.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  A comparison of four beta-adrenoceptor antagonists in patients with asthma.

Authors:  M K Benson; W T Berrill; J M Cruickshank; G S Sterling
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

Review 2.  Assessment of changes in airway calibre I. Tests of forced expiration.

Authors:  N B Pride
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

3.  Comparison of various methods for reading maximal expiratory flow-volume curves.

Authors:  R Peslin; A Bohadana; B Hannhart; P Jardin
Journal:  Am Rev Respir Dis       Date:  1979-02

4.  Site of airway obstruction in asthma as determined by measuring maximal expiratory flow breathing air and a helium-oxygen mixture.

Authors:  P J Despas; M Leroux; P T Macklem
Journal:  J Clin Invest       Date:  1972-12       Impact factor: 14.808

5.  The maximal expiratory flow-volume curve: its use in the detection of ventilatory abnormalities in a population study.

Authors:  R J Knudson; B Burrows; M D Lebowitz
Journal:  Am Rev Respir Dis       Date:  1976-11

6.  Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics.

Authors:  G Johnsson; N Svedmyr; G Thiringer
Journal:  Eur J Clin Pharmacol       Date:  1975-04-04       Impact factor: 2.953

7.  Significance of the relationship between lung recoil and maximum expiratory flow.

Authors:  J Mead; J M Turner; P T Macklem; J B Little
Journal:  J Appl Physiol       Date:  1967-01       Impact factor: 3.531

8.  Assessment of beta-adrenoceptor antagonists in asthmatic patients.

Authors:  R E Ruffin; E L McIntyre; K M Latimer; H E Ward; A J Crockett; J H Alpers
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

9.  [Propranolol and pindolol in chronic obstructive lung disease (author's transl)].

Authors:  W T Ulmer; K Lanser
Journal:  Dtsch Med Wochenschr       Date:  1976-11-26       Impact factor: 0.628

10.  Comparison of atenolol and oxprenolol in patients with angina or hypertension and co-existent chronic airways obstruction.

Authors:  W H Perks; S S Chatterjee; R S Croxson; J M Cruickshank
Journal:  Br J Clin Pharmacol       Date:  1978-02       Impact factor: 4.335

View more
  10 in total

Review 1.  Beta-adrenoceptor partial agonists: a renaissance in cardiovascular therapy?

Authors:  D G Waller
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

Review 2.  Adverse reactions and interactions with beta-adrenoceptor blocking drugs.

Authors:  R V Lewis; D G McDevitt
Journal:  Med Toxicol       Date:  1986 Sep-Oct

3.  Respiratory function in the elderly and the effects of beta blockade.

Authors:  A E Tattersfield
Journal:  Cardiovasc Drugs Ther       Date:  1991-01       Impact factor: 3.727

4.  Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease.

Authors:  R Fogari; A Zoppi; F Tettamanti; L Poletti; G Rizzardi; G Fiocchi
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

5.  Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension.

Authors:  Mihaela S Stefan; Michael B Rothberg; Aruna Priya; Penelope S Pekow; David H Au; Peter K Lindenauer
Journal:  Thorax       Date:  2012-08-31       Impact factor: 9.139

Review 6.  Adverse reactions with beta-adrenoceptor blocking drugs. An update.

Authors:  R V Lewis; C Lofthouse
Journal:  Drug Saf       Date:  1993-10       Impact factor: 5.606

Review 7.  Cardioselective beta-blockers for chronic obstructive pulmonary disease.

Authors:  S Salpeter; T Ormiston; E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

Review 8.  Defining and targeting health disparities in chronic obstructive pulmonary disease.

Authors:  Roy A Pleasants; Isaretta L Riley; David M Mannino
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-10-04

Review 9.  Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions.

Authors:  Khaled Albouaini; Mohammed Andron; Albert Alahmar; Mohaned Egred
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

10.  The safety of beta-blocker use in chronic obstructive pulmonary disease patients with respiratory failure in the intensive care unit.

Authors:  Feyza Kargin; Huriye Berk Takir; Cuneyt Salturk; Nezihe Ciftaslan Goksenoglu; Can Yucel Karabay; Ozlem Yazicioglu Mocin; Nalan Adiguzel; Gokay Gungor; Merih Kalamanoglu Balci; Murat Yalcinsoy; Ramazan Kargin; Zuhal Karakurt
Journal:  Multidiscip Respir Med       Date:  2014-02-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.